European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv)…
Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination…
Read More...
Read More...
